Jiangsu Aidea Pharmaceutical Co., Ltd. (688488.SS)
CNY 9.7
(1.68%)
CNY 9.7
(1.68%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 258.4 Million CNY | 133.95% |
| 2022 | 217.85 Million CNY | 64.97% |
| 2021 | 132.05 Million CNY | 36.28% |
| 2020 | 96.89 Million CNY | -2.28% |
| 2019 | 99.16 Million CNY | 2.26% |
| 2018 | 96.97 Million CNY | 18.8% |
| 2017 | 81.62 Million CNY | 22.91% |
| 2016 | 66.41 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 63.74 Million CNY | -12.78% |
| 2024 Q2 | 86.57 Million CNY | 35.83% |
| 2024 Q3 | 110.05 Million CNY | 5.04% |
| 2023 Q2 | 76.36 Million CNY | 45.75% |
| 2023 FY | 509.67 Million CNY | 133.95% |
| 2023 Q4 | 73.07 Million CNY | 29.28% |
| 2023 Q3 | 56.52 Million CNY | -25.98% |
| 2023 Q1 | 52.39 Million CNY | -0.82% |
| 2022 Q3 | 64.31 Million CNY | 6.45% |
| 2022 FY | 217.85 Million CNY | 64.97% |
| 2022 Q2 | 60.41 Million CNY | 49.9% |
| 2022 Q1 | 40.3 Million CNY | -21.19% |
| 2022 Q4 | 52.83 Million CNY | -17.85% |
| 2021 Q2 | 29.54 Million CNY | 34.09% |
| 2021 Q1 | 22.03 Million CNY | -32.92% |
| 2021 Q4 | 51.13 Million CNY | 74.32% |
| 2021 Q3 | 29.33 Million CNY | -0.71% |
| 2021 FY | 132.05 Million CNY | 36.28% |
| 2020 Q2 | 21.35 Million CNY | 38.18% |
| 2020 Q1 | 15.45 Million CNY | -54.0% |
| 2020 FY | 96.89 Million CNY | -2.28% |
| 2020 Q4 | 32.84 Million CNY | 21.42% |
| 2020 Q3 | 27.05 Million CNY | 26.67% |
| 2019 Q4 | 33.59 Million CNY | 39.41% |
| 2019 Q2 | 18.65 Million CNY | -17.92% |
| 2019 Q1 | 22.72 Million CNY | 0.0% |
| 2019 FY | 99.16 Million CNY | 2.26% |
| 2019 Q3 | 24.1 Million CNY | 29.18% |
| 2018 FY | 96.97 Million CNY | 18.8% |
| 2017 FY | 81.62 Million CNY | 22.91% |
| 2016 FY | 66.41 Million CNY | 0.0% |